The Drugs Controller General of India (DCGI) has approved the market authorization of India’s first quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Serum Institute of India (SII) will produce this vaccine. CEO of The Serum Institute of India Adar Poonawalla tweeted the information. For the first time, an inexpensive and widely available HPV vaccination made in India will be available to treat cervical cancer in female patients. Later this year, SII hopes to launch it, and we are grateful to the DCGI, MoHFW INDIA, for their approval.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV. The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15. After the vaccine’s phase 3 data were deemed to be satisfactory, suggestions were made.
Important Takeaways For All Competitive Exams:
Tactical ballistic missiles (TBMs) are short-range missiles designed primarily for battlefield use. Unlike intercontinental ballistic…
A new bill introduced by US House Republicans is stirring concern among immigrant communities, especially…
The Reserve Bank of India (RBI) has announced that it will soon release new Rs…
Navies are important parts of a country's military. They protect the seas, help during wars…
The month of May 2025 is filled with a series of significant national and international…
Many universities around the world have a long and rich history. Some of them were…
![](data:image/svg+xml;charset=utf-8,<svg height="218px" width="300px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
